Mereo BioPharma Group plc Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q1 2023 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Mereo BioPharma Group plc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q1 2023 to Q2 2024.
- Mereo BioPharma Group plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was -$12.3M, a 600% decline year-over-year.
- Mereo BioPharma Group plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$30M, a 30.1% increase from 2022.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)